Buprenorphine formulations for intranasal delivery
US7666876B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 19, 2002 |
| Grant date | Feb 23, 2010 |
| Priority date | — |
| Expiry date | Mar 19, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.